OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Atypical teratoid rhabdoid tumour (AT/RT)

A SMARCB1-deficient brain tumour of infants and young children: EZH2 inhibition and intensive chemotherapy.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:09 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
0
since 2026-07-14
New Ph2+ trials
0
Results posted
1
Readouts due
0
primary completion reached
Trial papers
2
PubMed, last 60 days
  1. Results posted
    Results posted: NCT04416568

    Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

  2. Paper
    Periodized Resistance Training Versus Aerobic Training in Managing Nonspecific Chronic Low Back Pain: A Randomized Controlled Trial.

    Mohammed AS, Youssef EF, Abdelnaeem AO. Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

    Publisher pageReports NCT06922981
  3. Paper

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.